Laura M Heath

Dr. Laura M Heath


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Nature Aging
Verified
Journal Article
Open access
PDF file
KPKatherine E. Prater
Katherine E. Prater
KGKevin J. Green
Kevin J. Green
SMSainath Mamde
Sainath Mamde
WSWei Sun
Wei Sun
ACAlexandra Cochoit
Alexandra Cochoit
SJSuman Jayadev
Suman Jayadev
Microglia, the innate immune cells of the brain, influence Alzheimer’s disease (AD) progression and are potential therapeutic targets. However, microglia exhibit diverse functions, the regulation of which is not fully understood, complicating therapeutics development. To better define the transcriptomic phenotypes and gene regulatory networks associated with AD, we enriched for microglia nuclei from 12 AD and 10 control human dorsolateral prefrontal cortices (7 males and 15 females, all aged >60 years) before single-nucleus RNA sequencing. Here we describe both established and previously unrecognized microglial molecular phenotypes, the inferred gene networks driving observed transcriptomic change, and apply trajectory analysis to reveal the putative relationships between microglial phenotypes. We identify microglial phenotypes more prevalent in AD cases compared with controls. Further, we describe the heterogeneity in microglia subclusters expressing homeostatic markers. Our study demonstrates that deep profiling of microglia in human AD brain can provide insight into microglial transcriptional changes associated with AD.

12 April 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LHLaura M Heath
Laura M Heath
JEJohn C. Earls
John C. Earls
AMAndrew T. Magis
Andrew T. Magis
SKSergey A. Kornilov
Sergey A. Kornilov
JLJennifer C. Lovejoy
Jennifer C. Lovejoy
NPNathan Price
Nathan Price
Genetics play an important role in late-onset Alzheimer’s Disease (AD) etiology and dozens of genetic variants have been implicated in AD risk through large-scale GWAS meta-analyses. However, the precise mechanistic effects of most of these variants have yet to be determined. Deeply phenotyped cohort data can reveal physiological changes associated with genetic risk for AD across an age spectrum that may provide clues to the biology of the disease. We utilized over 2000 high-quality quantitative measurements obtained from blood of 2831 cognitively normal adult clients of a consumer-based scientific wellness company, each with CLIA-certified whole-genome sequencing data. Measurements included: clinical laboratory blood tests, targeted chip-based proteomics, and metabolomics. We performed a phenome-wide association study utilizing this diverse blood marker data and 25 known AD genetic variants and an AD-specific polygenic risk score (PGRS), adjusting for sex, age, vendor (for clinical labs), and the first four genetic principal components; sex-SNP interactions were also assessed. We observed statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D, and APOE), with effects detectable from early adulthood. The ABCA7 SNP and the APOE2 and APOE4 encoding alleles were associated with lipid variability, as seen in previous studies; in addition, six novel proteins were associated with the e2 allele. The most statistically significant finding was between the NYAP1 variant and PILRA and PILRB protein levels, supporting previous functional genomic studies in the identification of a putative causal variant within the PILRA gene. We did not observe associations between the PGRS and any analyte. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. In post-hoc analysis, sex-stratified GWAS results from an independent AD case–control meta-analysis supported sex-specific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable. Known AD genetic variation influenced lipid metabolism and immune response systems in a population of non-AD individuals, with associations observed from early adulthood onward. Further research is needed to determine whether and how these effects are implicated in early-stage biological pathways to AD. These analyses aim to complement ongoing work on the functional interpretation of AD-associated genetic variants.

16 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
GCGa Cary
Ga Cary
JWJc Wiley
Jc Wiley
JGJ Gockley
J Gockley
SKS Keegan
S Keegan
LHLaura M Heath
Laura M Heath
TCThe Emory-Sage-Sgc Treat-Ad Center
The Emory-Sage-Sgc Treat-Ad Center
Alzheimer’s disease (AD) is the predominant dementia globally, with heterogeneous presentation and penetrance of clinical symptoms, variable presence of mixed pathologies, potential disease subtypes, and numerous associated endophenotypes. Beyond the difficulty of designing treatments that address the core pathological characteristics of the disease, therapeutic development is challenged by the uncertainty of which endophenotypic areas and specific targets implicated by those endophenotypes to prioritize for further translational research. However, publicly-funded consortia driving large-scale open science efforts have produced multiple omic analyses that address both disease risk relevance and biological process involvement of genes across the genome. Here we report the development of an informatic pipeline that draws from genetic association studies, predicted variant impact, and linkage with dementia associated phenotypes to create a genetic risk score. This is paired with a multi omic risk score utilizing extensive sets of both transcriptomic and proteomic studies to identify systems level changes in expression associated with AD. These two elements combined constitute our target risk score that ranks AD risk genomewide. The ranked genes are organized into endophenotypic space through the development of 19 biological domains associated with AD in the described genetics and genomics studies and accompanying literature. The biological domains are constructed from exhaustive gene ontology (GO) term compilations, allowing automated assignment of genes into objectively defined disease-associated biology. This rank and organize approach, performed genome-wide, allows the characterization of aggregations of AD risk across biological domains. The top AD-risk associated biological domains are Synapse, Immune Response, Lipid Metabolism, Mitochondrial Metabolism, Structural Stabilization, and Proteostasis, with slightly lower levels of risk enrichment present within the other 13 biological domains. This provides an objective methodology to localize risk within specific biological endophenotypes, and drill down into the most significantly associated sets of GO-terms and annotated genes for potential therapeutic targets.

20 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
LHLaura M Heath
Laura M Heath
JEJohn Earls
John Earls
AMAndrew Magis
Andrew Magis
SKSergey Kornilov
Sergey Kornilov
JLJennifer Lovejoy
Jennifer Lovejoy
NPNathan Price
Nathan Price
Background Genetics play an important role in late-onset Alzheimer’s Disease (AD) etiology and dozens of genetic variants have been implicated in AD risk through large-scale GWAS meta-analyses. However, the precise mechanistic effects of most of these variants have yet to be determined. Deeply phenotyped cohort data can reveal physiological changes associated with genetic risk for AD across an age spectrum that may provide clues to the biology of the disease. Methods We utilized over 2000 high-quality quantitative measurements obtained from blood of 2831 cognitively normal adult clients of a consumer-based scientific wellness company, each with CLIA-certified whole-genome sequencing data. Measurements included: clinical laboratory blood tests, targeted chip-based proteomics, and metabolomics. We performed a phenome-wide association study utilizing this diverse blood marker data and 25 known AD genetic variants, adjusting for sex, age, vendor (for clinical labs), and the first four genetic principal components; sex-SNP interactions were also assessed. Results We observed statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D, and APOE), with effects detectable from early adulthood. The ABCA7 SNP and the APOE2 and APOE4 encoding alleles were associated with lipid variability, as seen in previous studies; in addition, six novel proteins were associated with the e2 allele. The most statistically significant finding was between the NYAP1 variant and PILRA and PILRB protein levels, supporting previous functional genomic studies in the identification of a putative causal variant within the PILRA gene. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. In post-hoc analysis, sex-stratified GWAS results from an independent AD case-control meta-analysis supported sex-specific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable. Conclusions Known AD genetic variation influenced lipid metabolism and immune response systems in a population of non-AD individuals, with associations observed from early adulthood onward. Further research is needed to determine whether and how these effects are implicated in early-stage biological pathways to AD. These analyses aim to complement ongoing work on the functional interpretation of AD-associated genetic variants.

28 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LHLaura M Heath
Laura M Heath
JEJohn C. Earls
John C. Earls
AMAndrew T. Magis
Andrew T. Magis
SKSergey Kornilov
Sergey Kornilov
JLJennifer C. Lovejoy
Jennifer C. Lovejoy
NPNathan Price
Nathan Price
Deeply phenotyped cohort data can elucidate differences associated with genetic risk for common complex diseases across an age spectrum. Previous work has identified genetic variants associated with Alzheimer’s disease (AD) risk from large-scale genome-wide association study meta-analyses. To explore effects of known AD-risk variants, we performed a phenome-wide association study on ~2000 clinical, proteomic, and metabolic blood-based analytes obtained from 2,831 cognitively normal adult clients of a consumer-based scientific wellness company. Results uncovered statistically significant SNP-analyte associations for five genetic variants after correction for multiple testing (for SNPs in or near NYAP1, ABCA7, INPP5D , and APOE ). These effects were detectable from early adulthood. Sex modified the effects of four genetic variants, with multiple interrelated immune-modulating effects associated with the PICALM variant. Sex-stratified GWAS results from an independent AD case-control meta-analysis supported sexspecific disease effects of the PICALM variant, highlighting the importance of sex as a biological variable. These analyses support evidence from previous functional genomics studies in the identification of a causal variant within the PILRA gene. Taken together, this study highlights clues to the earliest effects of AD genetic risk variants in individuals where disease symptoms have not (yet) arisen.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ALAbby Vander Linden
Abby Vander Linden
ZLZoë Leanza
Zoë Leanza
JBJessica S Britton
Jessica S Britton
AKAmelia Kallaher
Amelia Kallaher
LHLaura M Heath
Laura M Heath
AGAnna K Greenwood
Anna K Greenwood
Background: The AD Knowledge Portal (https://adknowledgeportal.org) is a community‐driven resource developed to support transparent evaluation and broad use of resources generated within the translational research portfolio of the National Institute on Aging (NIA). This open access platform aims to accelerate Alzheimer’s disease (AD) research and maximize therapeutic discovery through sharing and re‐use of data in adherence with FAIR (Findable, Accessible, Interoperable, and Reproducible) principles. The AD Portal allows the AD research community to find curated and contextualized data, evaluate hypotheses via independent experiments, and prioritize new mechanisms for therapeutic development.Method: The AD Portal empowers researchers to share multi‐omics human and non‐human data with appropriate attribution for re‐use, and in compliance with necessary data governance and ethical guardrails. This is accomplished through the use of the secure Synapse data sharing platform–an NIH‐supported generalist repository–and a user‐friendly data portal website.Result: The AD Portal currently hosts resources from nine research consortia and more than 50 grants related to dementia and aging. Data from over 15,000 individuals and 30,000 specimens–encompassing central and peripheral samples from brain banks, longitudinal cohorts, and model systems–are available. While the organizing focus is aging and dementia, the provided data are generated through a broad array of modalities, including genomics, transcriptomics, epigenetics, imaging, immunoassays, mass spectrometry‐based proteomics and metabolomics, behavioral assays, and more. In addition to raw and processed data, portal users can explore open‐access experimental mouse models, computational tools, publications, and summarized evidence for putative AD targets via integrated results explorers.Conclusion: The AD Knowledge Portal offers the research community an accessible source of data, tools, and results for the study of AD and related dementias.